Last reviewed · How we verify
Levodopa-carbidopa intestinal gel
Levodopa-carbidopa intestinal gel delivers dopamine precursor (levodopa) directly to the small intestine via continuous infusion, bypassing gastric degradation and improving motor symptom control in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel delivers dopamine precursor (levodopa) directly to the small intestine via continuous infusion, bypassing gastric degradation and improving motor symptom control in advanced Parkinson's disease. Used for Advanced Parkinson's disease with motor fluctuations inadequately controlled by oral levodopa-carbidopa.
At a glance
| Generic name | Levodopa-carbidopa intestinal gel |
|---|---|
| Also known as | ABT-SLV187, LCIG, Duodopa, Duopa, Carbidopa-levodopa enteral suspension (CLES) |
| Sponsor | AbbVie |
| Drug class | Dopamine precursor combination therapy |
| Target | Dopamine pathway (levodopa → dopamine via aromatic amino acid decarboxylase) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Levodopa is converted to dopamine in the brain to replace depleted neurotransmitter levels in Parkinson's disease. Carbidopa is a decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine in the periphery, allowing more levodopa to reach the brain. Intestinal gel delivery provides continuous, steady-state absorption, reducing motor fluctuations and "off" periods experienced with oral dosing.
Approved indications
- Advanced Parkinson's disease with motor fluctuations inadequately controlled by oral levodopa-carbidopa
Common side effects
- Nausea
- Dyskinesia
- Abdominal pain
- Constipation
- Peripheral edema
- Infection at infusion site
Key clinical trials
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
- Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
- Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease (NA)
- INfusion VErsus STimulation in Parkinson's Disease (PHASE4)
- A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects (PHASE1)
- A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) (PHASE3)
- Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levodopa-carbidopa intestinal gel CI brief — competitive landscape report
- Levodopa-carbidopa intestinal gel updates RSS · CI watch RSS
- AbbVie portfolio CI